Thermostable vaccines could capture at least 20% of the global vaccine market over the next decade. In 2021, the WHO reported 94 vaccine distributors worldwide, with China and India leading, hosting 23 and 7 manufacturers respectively. Together, they accounted for 32% of Western Pacific-based manufacturers, with the region housing 41% of all vaccine producers globally.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5117
The World Health Organization estimates that immunization prevents 3.5-5 million deaths annually from diseases such as diphtheria, tetanus, pertussis, influenza, and measles, but cold storage issues damage vaccines. Thermostable vaccines can be stored at room temperature for extended periods, eliminating the need for cold chain logistics. This reduces storage and transportation costs, making mass immunization projects more affordable.
A thermostable vaccine is a type of vaccine that can maintain its effectiveness even when exposed to fluctuations in temperature. Unlike traditional vaccines that require strict refrigeration to preserve their potency, thermostable vaccines can remain viable even if not cold. This is particularly advantageous in regions with limited access to reliable refrigeration facilities, such as remote areas or during emergencies.
The importance of thermostable vaccines lies in their ability to overcome logistical challenges associated with vaccine storage and transportation. Maintaining a cold chain for vaccine distribution can be difficult in many parts of the world, especially in developing countries or areas with limited infrastructure. Thermostable vaccines solve this problem by eliminating the need for continuous refrigeration, thus expanding access to immunization programs and ensuring that more people, especially those in underserved communities, can receive vital vaccinations.
Tuberculosis (TB) spreads when sick people breathe the bacteria into the air. In 2021, TB caused 1.6 million deaths and affected 10.6 million people. The World Health Organization says almost two billion people worldwide have TB bacteria inside them. Thermostable vaccines can help manage TB.
Recent Update
- In March 2023, the Access to Advanced Health Institute (AAHI) released findings from a Phase I clinical trial showcasing the safety and effectiveness of a novel thermostable vaccine for tuberculosis (TB), the second leading cause of global infectious disease-related deaths. This TB vaccine contains various proteins from the Mycobacterium tuberculosis bacterium fused into a single protein (ID93), coupled with a specialized immune-boosting adjuvant (GLA-SE). The vaccine is presented in a freeze-dried form that doesn’t need refrigeration.
Recent Developments
- In June 2023, the Department of Biotechnology (DBT) obtained emergency approval for GEMCOVAC-OM, a thermostable booster vaccine based on mRNA technology explicitly targeting the omicron variant. This vaccine integrates indigenous platform technology.
- In April 2023, AstriVax was awarded a EUR 2.5 million grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency to improve its thermostable vaccine platform.
Thermostable Vaccine Market Companies
- Serum Institute of India
- Sanofi
- GSK
- Hilleman Laboratories
- Soligenix
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/thermostable-vaccine-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5117
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
